Migraine Relief: Promising Results for STS101 Nasal Powder

Research Summary

A study published in the journal Headache evaluated participants' impressions of using STS101, a dihydroergotamine nasal powder, over 12 months in the ASCEND study. This open-label, single-arm study involved adults with a history of migraines, allowing self-administration of STS101 to treat attacks. Participants reported favorable impressions of the nasal powder, with over 90% finding it easy to use and 73-81% indicating they would likely use it if available. Compared to their usual medication, 64-74% believed STS101 helped them return to normal faster, worked faster, and worked more consistently. Exploratory data showed significant freedom from headache pain and symptoms postdose.

Study Details

📄 Title: Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open-label ASCEND acute migraine study.

👥 Research Team: Ailani J et al.

📚 Published In: Headache

📅 Publication Date: 2025 Nov 4

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.